Skip to content

Construction of an Early Severe Risk Warning Model for Childhood Community-Acquired Pneumonia: A Multicenter Cohort Study of Machine Learning Based on Dynamic Cytokine Changes

Construction of an Early Severe Risk Warning Model for Childhood Community-Acquired Pneumonia: A Multicenter Cohort Study of Machine Learning Based on Dynamic Cytokine Changes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127361
Enrollment
Unknown
Registered
2026-06-30
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Community-Acquired Pneumonia

Interventions

Childhood Community-Acquired Pneumonia Group:None

Sponsors

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1.Children aged from 29 days to 18 years old, both genders are eligibl; 2.?Baseline sample collection shall be completed within 48 hours after admission for patients meeting the pneumonia diagnostic criteria; 3.Voluntarily sign the informed consent form before the trial, and agree to participate in all scheduled visits, examinations and treatments in accordance with the requirements of the study protocol;

Exclusion criteria

Exclusion criteria: 1.Children with severe missing clinical data or whose outcomes cannot be traced; 2.Children with pneumonia secondary to severe infection at other sites (such as purulent meningitis, osteomyelitis, etc.); 3.Children with hospital-acquired pneumonia (HAP); 4.Underlying severe immune dysfunction: including tuberculosis infection, HIV positivity, primary immunodeficiency disease, patients with malignant tumor undergoing chemotherapy, and post-transplant patients; 5.Children with pneumonia characterized by persistent unhealed infection (disease course > 4 weeks) or repeated recurrence (recurrence > 2 times within 1 year); 6.Severe allergy history (e.g., previous anaphylaxis)?; 7.Exclusion for drug interference: Children who received systemic glucocorticoid therapy (intravenous infusion or oral administration) within 14 days before admission. **Note: Children who only received nebulized inhalation or local glucocorticoid therapy before admission can be included, but the drug name, dosage and frequency of use must be recorded in detail in the Case Report Form (CRF), and will be used as a adjusted covariate for subsequent analysis. 8.Children who have used immunosuppressants (such as cyclophosphamide, cyclosporine, etc.) or biological agents within 14 days before admission;

Design outcomes

Primary

MeasureTime frame
Day-28 mortality;Whether the condition progresses to severe pneumonia;

Secondary

MeasureTime frame
Days of mechanical ventilation in mechanically ventilated patients;Changes in oxygenation index in children with severe illness;Duration of fever (calculated in hours or days);Total length of hospital stay and length of ICU stay;90-day all-cause mortality;

Countries

China

Contacts

Public ContactYingxia Zheng

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

zhengyingxia@xinhuamed.com.cn+86 13585624293

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026